Bharat Biotech's Nasal Vaccine Rolls Out Today Amid Covid Scare. All You Need To Know

Nasal COVID-19 Vaccine: Those who have taken Covishield and Covaxin as primary doses can take the nasal vaccine as a booster dose.

A health worker with swab samples collected from people for Covid-19 tests, in Gurugram

Source : PTI

Amid a sharp uptick in Covid-19 cases globally, especially in neighbouring China, the government on Friday approved Bharat Biotech's intranasal vaccine as a booster dose for those aged 18 years and above. 

The vaccine, named iNCOVACC, had received approval of the drugs regulator in November for restricted use in an emergency situation as a heterologous booster dose. Heterologous booster means a person can be administered a different vaccine as a third shot from the one that he/she received as the primary dose.

As India steps up surveillance to thwart a possible Covid wave, the Centre has appealed to eligible citizens to get their booster or precautionary third dose. The coverage of the precautionary dose has been inadequate.

So far, about 22.35 crore booster doses have been administered, which is just 27 per cent of the total population eligible for boosters.

READ | Pill For Covid Does Not Reduce Hospitalisation Or Death Risk, Finds A UK Study

Here Is All You Need To Know About The Availability Of Nasal Vaccine

• The two-drop needle-free nasal vaccine is likely to be introduced on the Co-WIN platform from Friday evening and eligible people can book their shot from the mobile application ior website.
• The nasal vaccine will be available only at private hospitals as of now.
• iNCOVACC is stable at 2-8 degrees Celsius for easy storage and distribution.
• It can only be taken as a precaution or third dose by adults who have been vaccinated with two doses of either Covishield or Covaxin.
• In this case, the vaccine dose is given via nose, rather than orally or through the arm. The target is to deliver the dose into the respiratory pathways. The vaccine is either injected through a specific nasal spray.
• Nasal vaccines are easy to administer and builds up immune barriers in the respiratory tract through which respiratory viruses enter the body.
• It must be noted that the respiratory tract epithelium is the key entry point for the novel coronavirus.
• iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein.